JP2020063263A5 - - Google Patents

Download PDF

Info

Publication number
JP2020063263A5
JP2020063263A5 JP2019217044A JP2019217044A JP2020063263A5 JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5 JP 2019217044 A JP2019217044 A JP 2019217044A JP 2019217044 A JP2019217044 A JP 2019217044A JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5
Authority
JP
Japan
Prior art keywords
hematopoietic stem
cells
pge
activity
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019217044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020063263A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020063263A publication Critical patent/JP2020063263A/ja
Publication of JP2020063263A5 publication Critical patent/JP2020063263A5/ja
Priority to JP2023001015A priority Critical patent/JP2023052244A/ja
Withdrawn legal-status Critical Current

Links

JP2019217044A 2008-11-06 2019-11-29 造血幹細胞の生着手順を強化するための材料および方法 Withdrawn JP2020063263A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023001015A JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11201808P 2008-11-06 2008-11-06
US61/112,018 2008-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017195168A Division JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023001015A Division JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Publications (2)

Publication Number Publication Date
JP2020063263A JP2020063263A (ja) 2020-04-23
JP2020063263A5 true JP2020063263A5 (OSRAM) 2020-09-03

Family

ID=42153284

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011534934A Expired - Fee Related JP5846915B2 (ja) 2008-11-06 2009-11-06 造血幹細胞の生着手順を強化するための材料および方法
JP2015134076A Expired - Fee Related JP6632822B2 (ja) 2008-11-06 2015-07-03 造血幹細胞の生着手順を強化するための材料および方法
JP2017195168A Withdrawn JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法
JP2019217044A Withdrawn JP2020063263A (ja) 2008-11-06 2019-11-29 造血幹細胞の生着手順を強化するための材料および方法
JP2023001015A Pending JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011534934A Expired - Fee Related JP5846915B2 (ja) 2008-11-06 2009-11-06 造血幹細胞の生着手順を強化するための材料および方法
JP2015134076A Expired - Fee Related JP6632822B2 (ja) 2008-11-06 2015-07-03 造血幹細胞の生着手順を強化するための材料および方法
JP2017195168A Withdrawn JP2018048156A (ja) 2008-11-06 2017-10-05 造血幹細胞の生着手順を強化するための材料および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023001015A Pending JP2023052244A (ja) 2008-11-06 2023-01-06 造血幹細胞の生着手順を強化するための材料および方法

Country Status (10)

Country Link
US (5) US9107909B2 (OSRAM)
EP (3) EP3031907B1 (OSRAM)
JP (5) JP5846915B2 (OSRAM)
CN (4) CN102245758A (OSRAM)
AU (4) AU2009313290B2 (OSRAM)
CA (3) CA3203374A1 (OSRAM)
ES (1) ES2845641T3 (OSRAM)
PT (1) PT3031907T (OSRAM)
WO (1) WO2010054271A1 (OSRAM)
ZA (1) ZA201804932B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN06624A (OSRAM) 2005-10-18 2015-07-10 Univ Colorado
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
EP2603227B1 (en) * 2010-08-12 2017-10-04 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
ES2693622T3 (es) 2011-01-13 2018-12-13 SciPharm S.à r.l. Método para mejorar el injerto de células madre hematopoyéticas
EP3269802B1 (en) 2011-09-30 2019-10-23 Bluebird Bio, Inc. Compounds for improved viral transduction
PT2785834T (pt) * 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
US10111907B2 (en) * 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
WO2013130499A1 (en) * 2012-02-29 2013-09-06 University Of Virginia Patent Foundation Compositions and methods for cxcr4 signaling and umbilical cord blood stem cell engraftment
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
AU2013292330B2 (en) * 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
WO2014026110A2 (en) * 2012-08-10 2014-02-13 Bluebird Bio, Inc. Compounds for improved viral transduction
KR20160023638A (ko) 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP3030232B1 (en) 2013-04-29 2022-07-06 Medregen, LLC Wound healing via autologous stem cell mobilization
KR101489861B1 (ko) * 2013-05-07 2015-02-05 경북대학교 산학협력단 Amd3100을 포함하는 골질환 예방 또는 치료용 조성물
EP3250682A4 (en) 2015-01-26 2018-08-01 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN104774806B (zh) * 2015-04-09 2019-02-15 广州赛莱拉干细胞科技股份有限公司 一种胎盘造血干细胞的制备方法
KR20180033537A (ko) 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
RU2021103425A (ru) 2016-02-12 2021-02-25 Блубёрд Био, Инк. Композиции, повышающие число копий вектора (чкв), и способы их применения
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
WO2018017341A1 (en) * 2016-07-22 2018-01-25 Senlin Li Methods and compositions for rejuvenation
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
AU2018212854B2 (en) * 2017-01-27 2024-06-20 Children's Hospital Medical Center Methods of enhancing engraftment activity of hematopoietic stem cells
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11213546B2 (en) 2017-09-07 2022-01-04 Emory University Methods to mobilize tissue resident cells for adoptive t cell therapy
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
CN108404112B (zh) * 2018-04-01 2020-05-12 北京诺赛启研再生医学研究院有限公司 提高造血干细胞归巢及植入率的方法及其试剂
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ,インク. T細胞疲弊を処置するための組成物および方法
KR20220160018A (ko) 2020-03-31 2022-12-05 덴카 주식회사 알루미나 분말, 수지 조성물, 및 방열 부품
CN116509834B (zh) * 2023-01-20 2025-05-13 东北师范大学 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
EP1461087A1 (en) 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
WO2003065871A2 (en) 2002-02-04 2003-08-14 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
CA2519975C (en) 2003-04-08 2013-07-02 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
JP5315611B2 (ja) * 2004-06-23 2013-10-16 小野薬品工業株式会社 S1p受容体結合能を有する化合物およびその用途
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2007041511A2 (en) * 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
JP2007099724A (ja) 2005-10-06 2007-04-19 Shizuoka Prefecture スルファチドを標的とした抗ウイルス剤
US8076315B2 (en) * 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
MX373998B (es) * 2006-03-24 2020-07-22 Childrens Medical Center Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc.
EP2049129B1 (en) 2006-06-22 2013-06-12 Yeda Research And Development Co., Ltd. Catecholamine receptor modulation
EP3824885A1 (en) 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US8598328B2 (en) 2006-12-13 2013-12-03 National University Corporation Nagoya University Tol1 factor transposase and DNA introduction system using the same
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
EP3269802B1 (en) 2011-09-30 2019-10-23 Bluebird Bio, Inc. Compounds for improved viral transduction

Similar Documents

Publication Publication Date Title
ES2401608T3 (es) Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
MY197586A (en) Adenovirus armed with bispecific t cell engager (bite)
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
ES2900560T3 (es) Terapia génica.
JP2018184448A5 (OSRAM)
MX2025013445A (es) Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado
MY209906A (en) Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
MX2021001292A (es) Metodos para la modificacion genica de celulas hematopoyeticas.
MX2022010363A (es) Formulaciones clinicas.
MX2020005663A (es) Terapia genica para mucopolisacaridosis iii a.
MX2024012761A (es) Terapia genica con el atanogeno 3 asociado a linfoma de celulas b 2 (bag3) utilizando el vector aav
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
Zhou et al. IFNα‐expressing amniotic fluid‐derived mesenchymal stem cells migrate to and suppress HeLa cell‐derived tumors in a mouse model
Petersen et al. Efficient transduction of equine adipose-derived mesenchymal stem cells by VSV-G pseudotyped lentiviral vectors
JP2019068814A5 (OSRAM)
Perlea et al. Phenotype heterogeneity in dental pulp stem niches
CA3217059A1 (en) Compositions for improving the transduction of cells by viral vectors
Yusoff et al. A comparison of culture characteristics between human amniotic mesenchymal stem cells and dental stem cells
Aizenshtadt et al. Charachterization of umbilical cord mesenchymal stromal cells during long-term expansion in vitro
ATE481495T1 (de) Adenovirusvektor
Hoetzenecker Step by step toward the summit
George et al. Editing of highly homologous gamma-globin genes by nickase deficient Base Editor mitigates large intergenic deletions
Nicholson et al. 118. Inhibition of Hepatitis B Virus Replication In Vivo Following Delivery of Antiviral TALENs With Recombinant Adeno-Associated Viral Vectors
MY190213A (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues